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Abstract
Insulin resistance is a major predictor of the development of metabolic disorders. Sirtuins (SIRTs) have emerged as potential
targets that can be manipulated to counteract age-related diseases, including type 2 diabetes. SIRT2 has been recently shown
to exert important metabolic effects, but whether SIRT2 regulates insulin sensitivity in hepatocytes is currently unknown.
The aim of this study is to investigate this possibility and to elucidate underlying molecular mechanisms. Here, we show that
SIRT2 is downregulated in insulin-resistant hepatocytes and livers, and this was accompanied by increased generation of re-
active oxygen species, activation of stress-sensitive ERK1/2 kinase, and mitochondrial dysfunction. Conversely, SIRT2 overex-
pression in insulin-resistant hepatocytes improved insulin sensitivity, mitigated reactive oxygen species production and
ameliorated mitochondrial dysfunction. Further analysis revealed a reestablishment of mitochondrial morphology, with a
higher number of elongated mitochondria rather than fragmented mitochondria instigated by insulin resistance.
Mechanistically, SIRT2 was able to increase fusion-related protein Mfn2 and decrease mitochondrial-associated Drp1. SIRT2
also attenuated the downregulation of TFAM, a key mtDNA-associated protein, contributing to the increase in mitochondrial
mass. Importantly, we found that SIRT2 expression in PBMCs of human subjects was negatively correlated with obesity and
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insulin resistance. These results suggest a novel function for hepatic SIRT2 in the regulation of insulin sensitivity and raise
the possibility that SIRT2 activators may offer novel opportunities for preventing or treating insulin resistance and type 2
diabetes.
Introduction
Insulin resistance is a pathophysiological hallmark of metabolic
disorders, including obesity and type 2 diabetes, whose incidence
has risen to epidemic proportions globally. In the liver, insulin re-
sistance results from the inability of insulin to stimulate hepatic
glycogen synthesis and to suppress hepatic glucose production,
thus leading to both fasting and postprandial hyperglycemia (1).
Despite extensive research, the mechanisms underlying insulin
resistance remain incompletely understood (2). It is now recog-
nized that oxidative stress and mitochondrial dysfunction are im-
portant contributors to obesity-induced insulin resistance (3–5).
Alleviating insulin resistance is still one of the key therapeutic
avenues currently available for type 2 diabetes.
Mammalian sirtuins are a conserved family of proteins
(SIRT1-7) with NADþ-dependent deacetylase and/or ADP ribo-
syltransferase activities, linking their enzymatic activity to
the energy state of the organism. Sirtuins are implicated in a
myriad of biological processes, including lifespan regulation,
metabolism and stress response pathways (6–8). Manipulating
their activity may positively impact upon metabolic and age-
related disorders (9).
SIRT2 is localized mainly in the cytosol, but can transiently
shuttle to the nucleus during mitosis (10). To date, SIRT2 has been
ascribed crucial roles in cell cycle regulation (11,12), neurodegener-
ation (13,14), tumor suppression (12,15) and inflammation (16,17).
Accumulating evidence suggests that SIRT2 is an important
element on cellular metabolic regulation (18); however, a link be-
tween SIRT2 and hepatic insulin resistance has not yet been
established. Interestingly, SIRT2 is the most abundant sirtuin in
mouse adipose tissue (19), where it is induced by calorie restriction
(20,21). Conversely, SIRT2 is downregulated in visceral adipose
tissue from human obese subjects (22). SIRT2 also regulates adipo-
cyte differentiation (19,23), sterol and fatty acid biosynthesis (14)
and energy expenditure (22). Furthermore, there is evidence sug-
gesting that SIRT2 is able to mitigate oxidative stress and inflam-
mation by deacetylating the redox-sensitive transcription factors
forkhead box class O (FOXO) (21) and nuclear factor-jB (NF-jB)
(17,24), conditions intimately intertwined with insulin resistance
(3–5,25). Importantly, recent studies have shown that SIRT2
interacts with and regulates Akt activation in insulin-responsive
cells (26,27).
Based on these premises, we hypothesized that SIRT2 activa-
tion may restore metabolic homeostasis and improve insulin
sensitivity. Thus, the present study sought to provide evidence
that SIRT2 is involved in the regulation of insulin sensitivity in
hepatocytes. We find that SIRT2 is downregulated in both
insulin-resistant hepatocytes and livers as well as in blood cells
from obese and insulin-resistant human subjects, and this
is mechanistically linked to high levels of oxidative stress,
mitochondrial dysfunction, decreased mitochondrial mass and
fragmented mitochondrial network, supporting a derangement
in mitochondrial dynamics. Interestingly, we observe that
SIRT2 overexpression in hepatocytes improves insulin sensitiv-
ity, attenuates reactive oxygen species (ROS) production and
mitochondrial dysfunction, and ameliorates all mitochondrial
changes. Our data uncover SIRT2 as an important regulator of
insulin sensitivity in hepatocytes and suggest that SIRT2
activation might be a useful strategy in type 2 diabetes and
other insulin-resistant states.
Results
Reduced hepatic SIRT2 expression under insulin-
resistant conditions
Given the ubiquitous expression pattern of SIRT2 and its biolog-
ical importance in several metabolic pathways (18), together
with the central role of the liver in controlling glucose and lipid
metabolism, we hypothesized that SIRT2 might have a role in
hepatic insulin sensitivity. For this purpose, we first studied
the leptin-deficient ob/ob mouse, a well-characterized genetic
model of severe obesity and insulin resistance (28). As expected,
ob/ob mice were heavier, had higher epididymal adipose tissue
and liver masses, and were hyperglycemic and hyperinsuline-
mic relative to wild-type (WT) control mice (Table 1). In addi-
tion, homeostatic model assessment of insulin resistance
(HOMA-IR) indexes of ob/ob mice were 8-fold increased when
compared with WT controls (Fig. 1A). Since increased ROS pro-
duction appears to trigger insulin resistance in several contexts
(5,29), we thus quantified hydrogen peroxide (H2O2) levels in WT
and insulin-resistant mice. In livers of ob/ob mice, H2O2 produc-
tion was significantly higher in comparison with control mice,
indicating an increase in oxidative stress (Fig. 1B). There is evi-
dence that oxidative stress-induced MAPK activation plays a
significant role in the development of insulin resistance (30).
Accordingly, we observed an increase in the phosphorylation
state of extracellular signal-regulated kinase (ERK) 1/2 in livers
of ob/ob mice as compared with control mice (Fig. 1C). We then
assessed SIRT2 protein expression in livers of ob/ob mice and
control mice. SIRT2 can be synthesized in two different forms as
the result of alternative splicing (31). Protein levels of SIRT2 long
isoform were significantly reduced in livers of ob/ob mice
as compared with the control group, whereas the short
isoform was not altered (Fig. 1D). To determine whether these
findings are also observed in a mouse model of high fat diet
(HFD)-induced obesity and insulin resistance, we evaluated
gene expression patterns in an existing liver tissue dataset (32).
Transcriptomic analysis in livers of these mice showed
decreased levels of SIRT2 while some genes involved in lipid
metabolism and markers of fibrosis and inflammation exhibited
opposite trend, such as Col3a1, Ccl2, Ccr2 and Pparg (Fig. 1E).
To experimentally corroborate these genomics derived data, we
examined mice fed a HFD for 21 weeks. Due to excessive energy
intake, these mice exhibited higher body weight (CD: 31.46 0.9 g
versus HFD: 41.262.1 g) that was accompanied by higher fasting
glucose levels, a standard indicative of insulin resistance
(Fig. 1F). Parallel to what was observed in ob/ob mice, HFD-fed
mice displayed lower levels of SIRT2 (Fig. 1G). Taken together,
these results suggest a link between insulin resistance and di-
minished levels of SIRT2 expression.
We next investigated whether SIRT2 expression is also
decreased in a cellular model of insulin resistance. Consistent
with previous work (33,34), treatment with glucosamine (GlcN) at
a nontoxic concentration for 24 h suppressed insulin-stimulated
glycogen synthesis in HepG2 cells (Fig. 2A). Interestingly, the
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defect in insulin action could be rescued by pioglitazone, a
member of the thiazolidinedione class of insulin-sensitizing
drugs, lending physiological relevance to this model (Fig. 2A).
Pretreatment with N-acetylcysteine (35), a ROS scavenger, re-
versed GlcN-induced impairment of insulin-induced glycogen
synthesis (Fig. 2A), suggesting that oxidative stress underlies in-
sulin resistance in HepG2 cells. Whereas chronic ROS production
may contribute to the development of insulin resistance, increas-
ing evidence suggests that transient ROS generation in response
to insulin may be required for normal cellular signal transduction
(36). Therefore, we examined whether insulin-induced ROS levels
and subsequent ERK1/2 signaling were altered in insulin-
resistant cells. We found that the transient increase in H2O2 lev-
els in control cells in response to insulin (Fig. 2B) coincided with
elevated ERK1/2 phosphorylation (Fig. 2C), consistent with ROS
participating in normal insulin action. Interestingly, 30-min post-
treatment with insulin H2O2 levels returned to basal (Fig. 2C).
Similar to insulin-resistant mice, GlcN-treated cells exhibited
higher basal levels of H2O2 (Fig. 2B), which correlated with ERK1/2
hyperphosphorylation (Fig. 2C). Under these conditions, insulin
caused an exacerbation in H2O2 production (Fig. 2B), but failed to
enhance ERK1/2 activation (Fig. 2C). In line with our in vivo re-
sults, we found a reduction in the expression of both long and
short SIRT2 isoforms in insulin-resistant HepG2 cells (Fig. 2D).
Collectively, our in vivo and in vitro observations suggest that
hepatic SIRT2 expression is reduced in insulin resistant condi-
tions, possibly by a mechanism involving exaggerated ROS
production and consequent ERK1/2 phosphorylation.
SIRT2 overexpression restores insulin sensitivity in
insulin-resistant HepG2 cells by counteracting oxidative
stress and mitochondrial dysfunction
The reduction of SIRT2 expression under insulin-resistant
conditions led us to hypothesize that increasing the dosage of
SIRT2 may improve insulin sensitivity. To test this hypothesis,
we investigated the effect of SIRT2 overexpression on insulin-
stimulated glycogen synthesis and Akt phosphorylation. HepG2
cells were transfected with either wild-type SIRT2 (SIRT2-WT)
or a catalytically-inactive mutant (SIRT2-CI) (Fig. 3A). Under nor-
mal conditions, overexpressing either SIRT2-WT or SIRT2-CI did
not alter insulin-stimulated glycogen synthesis (Fig. 3B) or Akt
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Figure 1. Obese insulin resistant mice exhibit reduced levels of SIRT2 in the liver. (A) Insulin resistance as estimated by homeostatic model assessment of insulin resis-
tance (HOMA-IR) in wild-type (WT) and ob/ob mice. (B) H2O2 release from liver tissue of WT and ob/ob mice detected using Amplex Red and normalized to the sample
protein content. (C) Representative western blots showing phosphorylated ERK1/2 (P-ERK1/2) assessed in livers of WT and ob/ob mice. Immunoblot of total ERK1/2
served as the loading control. Lower panel shows densitometric analysis of P-ERK1/2 normalized to ERK1/2. (D) Representative western blots showing SIRT2 expression
in livers of WT and ob/ob mice. Two bands were observed, corresponding to the long (43 kDa) and short (39 kDa) isoforms of the SIRT2 proteins. GAPDH used as a loading
control. Lower panel shows densitometric analysis of SIRT2 bands normalized to GAPDH. (E) Heatmap displaying the relative expression of SIRT2 as well as markers of
fibrosis, inflammation and lipid metabolism-related genes in mice fed a high-fat diet (HFD) (32). (F) Fasting blood glucose levels in mice fed a standard chow diet (CD)
or a high-fat diet (HFD) for 21 weeks. (G) SIRT2 mRNA expression in livers of mice fed a CD or a HFD. Values are expressed as mean 6 SEM (n¼4–6 for each group;
*P<0.05, comparing the indicated groups).
Table 1. Anthropometric and metabolic parameters of wild-type and
ob/ob mice
Parameter Wild-type ob/ob P-value
Body weight (g) 18.661.9 43.163.0 <0.001
EpiWAT weight (g) 0.1660.05 1.5560.26 <0.001
Liver weight (g) 0.9360.08 2.8160.42 <0.001
Glucose (mg/dl) 162.766.7 350.2624.8 <0.001
Insulin (ng/ml) 1.6360.13 6.4360.71 <0.001
Data are expressed as mean6SEM. EpiWAT, epididymal white adipose tissue.
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phosphorylation (Fig. 3C). However, under GlcN-induced insu-
lin-resistant conditions, overexpression of SIRT2-WT, but not
SIRT2-CI, significantly enhanced insulin-stimulated glycogen
synthesis (Fig. 3B) and Akt phosphorylation, although this latter
parameter was only partially rescued (Fig. 3C). Overall, these
data indicate that increased expression of SIRT2 improves insu-
lin sensitivity under conditions of insulin resistance.
As oxidative stress and mitochondrial dysfunction have
been implicated in the etiology of insulin resistance (3–5), we
next tested whether upregulating SIRT2 expression affects ROS
production and mitochondrial oxygen consumption. Under nor-
mal conditions, overexpression of either SIRT2-WT or SIRT2-CI
had no effect on H2O2 production. Interestingly, under insulin-
resistance, enhanced expression of SIRT2-WT resulted in atten-
uated H2O2 levels, whereas no differences were observed upon
overexpression of the catalytically inactive SIRT2 (Fig. 4A).
Subsequently, we measured the oxygen consumption rate
(OCR) in intact HepG2 cells, using a Clark-type oxygen electrode,
which enables the evaluation of mitochondrial bioenergetics
under conditions that are more physiologically relevant as com-
pared to isolated mitochondria (37). We monitored the OCR in
the basal state and after the sequential addition of the ATPase
inhibitor oligomycin and the uncoupler FCCP, which stimulates
maximal mitochondrial respiration by dissipating the mito-
chondrial membrane potential (Fig. 4B). No statistically signifi-
cant differences in the level of basal respiration were observed
between control and SIRT2-overexpressing cells; in order to al-
low direct comparison of bioenergetic profiles between different
test conditions we therefore represent changes in respiration
relative to normalized basal OCR (Fig. 4C and D). Oligomycin de-
creased OCR to the same level in either SIRT2-WT or SIRT2-CI
cells under both experimental conditions, indicating that there
was no difference in non-coupled respiration. However, maxi-
mal OCR (after FCCP addition) and spare respiratory capacity
(SRC), a measure of mitochondrial fitness (37), were significantly
impaired in insulin-resistant cells (Fig. 4C–E), consistent
with SIRT2 deficiency causing profound respiratory defects.
Importantly, overexpression of SIRT2-WT, but not the deacety-
lase mutant, restored the ability of mitochondria to reach maxi-
mal respiratory capacity and SRC under insulin-resistant
conditions (Fig. 4D and E). Moreover, under normal conditions,
SIRT2 improved mitochondrial respiration (Fig. 4C and E). Taken
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Figure 2. GlcN-induced insulin resistance in HepG2 hepatocytes results in enhanced insulin-stimulated ROS production and decreased SIRT2 protein levels.
(A) Insulin-stimulated glycogen synthesis. Human HepG2 hepatocytes were pretreated with vehicle (Control) or GlcN (20 mM; 24 h) and then were left unstimulated or
stimulated with insulin (100 nM). Where indicated, pioglitazone (Pio) or N-acetylcysteine (NAC) were added simultaneously with GlcN. After 3 h, the cells were har-
vested and glycogen was quantified as described in Materials and Methods. Values were normalized to the respective basal glycogen synthesis. (B) Insulin-stimulated
H2O2 production. HepG2 cells were pretreated with vehicle (Control) or GlcN (20 mM; 24 h) and then stimulated with insulin (100 nM) for the indicated time.
Extracellular levels of H2O2 were determined in culture supernatants after incubation with Amplex red. (C) Representative western blots showing phosphorylated
ERK1/2 (P-ERK1/2) in HepG2 cells pretreated with vehicle or GlcN (20 mM; 24 h) before stimulation with insulin (100 nM; 15 min). Lower panel shows densitometric anal-
ysis of P-ERK1/2 normalized to actin. (D) Immunoblots showing SIRT2 levels in HepG2 cells treated with vehicle control or GlcN (20 mM; 24 h). Signals were quantified
by densitometry and normalized to actin. Values are expressed as mean 6 SEM (n¼3–6 for each group; *P<0.05, comparing the indicated groups; NS, not significant).
4108 | Human Molecular Genetics, 2017, Vol. 26, No. 21
Downloaded from https://academic.oup.com/hmg/article-abstract/26/21/4105/4036435
by Universidade do Porto user
on 04 April 2018
BC
A
Figure 3. Increased expression of wild-type SIRT2, but not a deacetylase mutant, restores insulin sensitivity in GlcN-treated cells. (A) HepG2 cells were transfected with
expression plasmids encoding GFP-tagged wild-type SIRT2 (SIRT2-WT) or a catalytically inactive mutant (SIRT2-CI). At 48 h post-transfection, cells were lysed and sub-
jected to western blotting using anti-GFP, anti-SIRT2 and anti-actin. Actin was used as loading control. (B) Insulin-stimulated glycogen synthesis. Cells were trans-
fected with the indicated plasmids and after 24 h cells were treated with vehicle (left panel) or GlcN (20 mM; 24 h, right panel) and then were left unstimulated or
stimulated with insulin (100 nM; 3h). Glycogen synthesis was subsequently assessed. (C) Insulin-stimulated Akt phosphorylation. Representative western blot of basal
and insulin-stimulated (100 nM; 15 min) Akt phosphorylation in HepG2 cells under the same conditions as in (B). Lower panels show densitometric analysis of P-Akt
normalized to total Akt. Values are expressed as mean 6 SEM (n¼3–6 for each group; *P<0.05, **P<0.01 comparing the indicated groups; NS, not significant).
4109Human Molecular Genetics, 2017, Vol. 26, No. 21 |
Downloaded from https://academic.oup.com/hmg/article-abstract/26/21/4105/4036435
by Universidade do Porto user
on 04 April 2018
together, these data indicate that SIRT2 attenuates ROS genera-
tion and mitochondrial dysfunction and improves insulin sensi-
tivity in hepatocytes.
SIRT2 deacetylase activity regulates TFAM-dependent
mitochondrial biogenesis and mitochondrial morphol-
ogy in insulin-resistant HepG2 cells
Considering the importance of mitochondrial dynamics to
the pathogenesis of insulin resistance (38,39), we therefore
hypothesized that SIRT2 could have a role in mitochondrial bio-
genesis and dynamics, thus justifying the improvement in OCR
measurements (Fig. 4C–E). Because a recent study reported that
SIRT2 localizes to the inner mitochondrial membrane in central
nervous system cells (40), we decided to evaluate the presence
of SIRT2 in cytosolic and mitochondrial-enriched fractions of
HepG2 cells. Although decreased levels of SIRT2 in GlcN-treated
cytosolic extracts reinforced the previous results (Fig. 2D), we
were not able to observe SIRT2 in the mitochondria (Fig. 5A).
Afterwards, HepG2 cells were co-transfected with SIRT2-WT or
A B
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Figure 4. SIRT2 overexpression attenuates ROS generation and improves mitochondrial oxygen consumption associated with insulin-resistant conditions.
(A) Extracellular H2O2 levels in HepG2 cells were determined 48 h post-transfection with the indicated plasmids. At 24 h post-transfection, cells were treated with either
vehicle or GlcN (20 mM; 24 h). (B) Sample trace demonstrating protocol followed for oxygen consumption measurements in intact HepG2 cells under basal conditions
and following the sequential addition of the mitochondrial inhibitor oligomycin (1 mg/ml) and the uncoupler FCCP (1 mM). Dashed lines represent extensions of oxygen
consumption rates before indicated additions to more clearly illustrate rate changes. (C, D) Oxygen consumption rates (OCR) relative to basal in HepG2 cells were deter-
mined under the experimental conditions described in panel A. The differences in OCR are derived from the calculated slope of oxygen utilization and normalized by
cell numbers in all assays. (E) Spare respiratory capacity (SRC) was calculated from data in panels C and D, as the difference between maximal FCCP-induced respira-
tion and basal respiration. Values are expressed as mean6SEM (n¼3-6 for each group; *P<0.05, compared with corresponding basal values; §P<0.05, compared with
corresponding values under insulin-sensitive conditions; #P<0.05, comparing the indicated groups).
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SIRT2-CI plasmids in combination with MitoDsRed to label
mitochondrial network. We observed reduced mitochondrial
content under GlcN-induced insulin resistant conditions, sus-
tained by a significant decrease in the protein levels of mito-
chondrial transcription factor A (TFAM) (Fig. 5B and C). Under
normal conditions, SIRT2 overexpression had no effect on mito-
chondrial content. In turn, SIRT2-WT completely recovered the
percentage of area occupied by mitochondria in GlcN-treated
hepatocytes to the levels of vehicle-treated cells, whereas cata-
lytic inactive SIRT2 was unable to increase the percentage of mi-
tochondrial mass (Fig. 5B). These results suggest that, although
SIRT2 does not seem to be present in the mitochondria, its
deacetylase activity is required to modulate TFAM-dependent
mitochondrial biogenesis.
According to the concept of unbalanced mitochondrial dy-
namics in insulin resistant conditions (41), we observed a sub-
stantial alteration in proteins participating in mitochondrial
fission and fusion after GlcN treatment. Under these conditions,
the dynamin-related protein 1 (Drp1), a large GTPase primarily
found in the cytosol, was shown to be enriched in the
mitochondrial fraction (Fig. 5D) where it triggers mitochondrial
fragmentation and eventually leads to mitochondria depolari-
zation. Similarly, immunocytochemistry analysis revealed in-
creased Drp1 co-localization with mitochondria in GlcN-treated
HepG2 cells (yellow arrows), in contrast to the more diffuse and
homogeneous labeling in vehicle conditions (Fig. 5E and I). In
addition, mitochondrial fusion-related protein mitofusin 2
(Mfn2) showed decreased protein levels, although no significant
changes were observed in optic atrophy 1 (Opa1) (Fig. 5F). Under
normal conditions, SIRT2 overexpression did not alter either
Drp1 co-localization with mitochondria or fusion protein levels;
however, under insulin resistant conditions SIRT2-WT signifi-
cantly decreased Drp1 in mitochondria and enhanced Mfn2 lev-
els, which was not observed with SIRT2-CI overexpression
(Fig. 5E, F and I). The decrease in the translocation of Drp1 to mi-
tochondria, combined with increased Mfn2 expression in the
outer mitochondrial membrane induced by SIRT2-WT overex-
pression ultimately led to an improvement of mitochondrial
morphology. While GlcN-treated HepG2 cells displayed a
dominant fragmented mitochondrial phenotype, represented
Figure 5. SIRT2 overexpression reestablishes mitochondrial mass and network in insulin-resistant HepG2 hepatocytes. (A) Immunoblots showing SIRT2 levels in mito-
chondrial (mito) and cytosolic (cyt) fractions of HepG2 cells pretreated with vehicle or GlcN (20 mM; 24 h). (B) The percentage of cellular area occupied by mitochondria
in HepG2 cells was determined 48 h after co-transfection with mitochondrial-targeted DsRed and SIRT2 (WT or CI); nuclei were stained with Hoechst. At 24 h post-
transfection, cells were treated with either vehicle or GlcN (20 mM; 24 h). (C) Under the same conditions, TFAM levels were detected by western blotting and normalized
for actin. Mitochondrial fission factor Drp1 was quantified in (D) cyt- and mito-enriched fractions by western blotting of HepG2 cells pretreated with vehicle or GlcN
(20 mM; 24 h) and (E) its co-localization with mitochondria (yellow arrows) was subsequently determined by immunocytochemistry. (F) Representative immunoblots of
fusion related proteins Mfn2 and Opa1. Actin was used as loading control. (G) Aspect ratio of individual mitochondrion was calculated for each condition using
MitoDsRed-transfected HepG2 cells to visualize their mitochondrial network. (H) Representative illustrations of fragmented mitochondria, mainly small, round and nu-
merous, and tubular mitochondria, with highly connected network. (I) Representative confocal images of HepG2 MitoDsRed/SIRT2-WT/CI co-transfected cells. Scale
bar: 10lm. Images were quantified in ImageJ considering 20 cells/condition/n. Values are expressed as mean 6 SEM (n¼3–4 for each group; *P<0.05, ****P<0.0001
compared with corresponding basal values; ##P<0.01, ####P<0.0001, comparing the indicated groups).
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graphically by lower aspect ratio, i.e. the ratio between the ma-
jor and minor axis of mitochondria that positively correlates
with length, SIRT2-WT insulin resistant HepG2 cells presented
predominant tubular mitochondrial network with higher aspect
ratio (Fig. 5G–I). The recovery of mitochondrial morphology
triggered by SIRT2-WT overexpression was not replicated under
conditions in which SIRT2 lacks deacetylase activity
(Fig. 5G and I). Overall, these findings support that SIRT2 directly
favors mitochondrial biogenesis and elongation in an insulin-
resistant hepatocyte cell model, which may reciprocally influ-
ence bioenergetics.
SIRT2 mRNA levels correlate inversely with obesity and
insulin resistance in humans
Finally, we investigated whether SIRT2 deficiency is associated
with obesity and insulin resistance in human individuals.
Clinical parameters of 45 Caucasian non-diabetic subjects strat-
ified into two groups according to the body mass index (BMI) are
presented in Table 2. In addition to a greater BMI, overweight
and obese subjects had higher fasting hyperinsulinemia and
hypertriglyceridemia. We observed a strong positive correlation
between insulin resistance, measured by the HOMA-IR index,
and obesity-related traits (BMI and waist circumference)
(Fig. 6A). To determine whether oxidative stress is increased in
these overweight and obese subjects, we measured lipid peroxi-
dation, a marker of oxidative injury. Lipid peroxidation, repre-
sented by plasma thiobarbituric acid reactive substance
(TBARS), was positively correlated with BMI and waist circum-
ference (Fig. 6A). Finally, we quantified SIRT2 mRNA expression
in PBMCs of the human subjects. Interestingly, SIRT2 mRNA levels
were negatively correlated with both indexes of obesity (BMI and
waist circumference) and insulin resistance (HOMA-IR) (Fig. 6B).
Taken together, these results suggest that SIRT2 downregulation
is associated with oxidative stress-related obesity and insulin re-
sistance in humans.
Discussion
The present study provides the first direct evidence that SIRT2
is involved in the regulation of hepatic insulin sensitivity. First,
we observed a reduction in SIRT2 expression levels in the livers
of both genetic and diet-induced obese and insulin-resistant
mice. Second, SIRT2 protein expression was significantly re-
duced in an insulin-resistant HepG2 cell model. Third, we found
that elevated SIRT2 expression improved insulin signaling and
enhanced insulin sensitivity in insulin-resistant HepG2 cells.
Finally, we found that SIRT2 gene expression in PBMCs from hu-
man subjects is inversely correlated with obesity and insulin re-
sistance. Taken together, these data suggest that positive
energy balance concomitant with insulin resistance in both ro-
dents and humans suppresses expression and potentially activ-
ity of SIRT2.
A growing body of literature supports a role for SIRT2 in the
regulation of important metabolic pathways (14,18,19,21–
23,42,43). However, available data on the role of SIRT2 in insulin
signaling have revealed contradictory findings. Consistent with
our results, recent studies showed that SIRT2 interacts with and
positively regulates Akt activation in insulin-responsive 3T3-L1
preadipocytes and HeLa cells (26) and in LUHMES neuronal cells
(44). While SIRT2 overexpression enhanced insulin-induced Akt
activation and phosphorylation of its downstream targets (26),
pharmacological or genetic SIRT2 inhibition causes the opposite
effect (26,44). In contrast, another study showed increased
SIRT2 expression in insulin-resistant C2C12 skeletal muscle
cells and that SIRT2 inhibition, by either pharmacological or ge-
netic means, increased insulin-stimulated glucose uptake and
improved phosphorylation of Akt and GSK3b under insulin
A
B
Figure 6. SIRT2 mRNA levels inversely correlate with obesity and insulin resis-
tance in humans. (A) Correlation of HOMA-IR and plasma TBARS with obesity
indexes (BMI and waist circumference). (B) Correlation between SIRT2 transcript
levels with obesity (BMI and waist circumference) and insulin resistance
(HOMA-IR) indexes in PBMCs from nondiabetic human subjects. Pearson‘s corre-
lation coefficient (r) is shown for each relationship. HOMA-IR, homeostatic
model assessment of insulin resistance; TBARS, thiobarbituric acid reactive sub-
stances; PBMCs, peripheral blood mononuclear cells.
Table 2. Anthropometric and metabolic parameters of human sub-
jects according to BMI category
Parameter BMI<25 BMI> 25 P-value
(n¼ 27) (n¼ 18)
Gender (M/F)a 10/17 8/10 0.852
Age (years) 21.5 6 0.6 22.2 6 1.8 0.567
BMI (kg/m2) 21.0 6 2.1 29.2 6 3.7 <0.001
Waist (cm) 71.4 6 6.5 92.7 6 9.7 <0.001
% fat 16.4 6 6.3 31.0 6 8.6 <0.001
Glucose (mg/dl) 83.2 6 6.4 86.8 6 8.6 0.109
Insulin (lU/ml) 8.8 6 3.1 13.0 6 6.0 0.015
HOMA-IR 1.8 6 0.7 2.8 6 1.4 0.015
Triglycerides (mg/dl) 76.8 6 26.7 110.1 6 42.5 0.011
Total cholesterol (mg/dl) 175.0 6 33.8 193.3 6 31.3 0.044
LDL (mg/dl) 104.7 6 29.6 116.8 6 21.5 0.036
HDL (mg/dl) 55.0 6 9.0 54.5 6 18.2 0.286
CRP (mg/l) 0.9 6 1.7 3.6 6 3.0 <0.001
Data are expressed as mean6SD.
aCategorical variables were compared using Chi-Square and continuous vari-
ables by Mann–Whitney test.
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resistance conditions, suggesting that SIRT2 may negatively af-
fect skeletal muscle glucose uptake (45). The discrepancy be-
tween these findings might be explained by differences in the
cellular models of insulin resistance. It is possible that SIRT2 in
different tissues may play distinctive and even opposing roles
with respect to insulin sensitivity. A similar scenario has been
previously reported for SIRT1, in which hepatic SIRT1 deficiency
leads to insulin resistance (46), whereas neuronal SIRT1 defi-
ciency improves insulin sensitivity in both brain and peripheral
tissues (47). Whether SIRT2 displays tissue-specific metabolic
actions has yet to be determined, but these studies suggest that
possibility.
The improvement in insulin sensitivity by SIRT2 appears to
be mediated, at least in part, by its effects on oxidative stress
and mitochondrial dysfunction, two conditions intimately asso-
ciated with insulin resistance (3–5,25). Multiple lines of evidence
from our data support this hypothesis. First, we observed in-
creased H2O2 levels in both insulin-resistant livers and cells,
and increased plasma TBARS, a lipid peroxidation marker, in
insulin-resistant humans, and this was associated with de-
creased SIRT2 mRNA levels. Second, we found that GlcN-
induced insulin resistance is associated with mitochondrial
dysfunction, as indicated by the inability of HepG2 cells to
achieve maximal respiration after addition of FCCP and low
spare respiratory capacity, suggesting reduced capacity to pro-
duce energy under conditions of increased work or stress (37).
Concordantly, in human fibroblasts, reduced levels of SIRT2
caused decreased oxidative phosphorylation and glycolysis acti-
vation (48). SIRT2 has been reported to suppress intracellular
ROS levels by deacetylating and thus activating FOXO3a-
dependent antioxidant defense mechanisms (21). Moreover, the
beneficial effect of SIRT2 against oxidative stress and mitochon-
drial dysfunction seems to be dependent on its catalytic activ-
ity, as overexpression of full length SIRT2, but not of a
catalytically inactive mutant, attenuated GlcN-induced ROS
production (Fig. 4A) and concomitantly restored FCCP-induced
maximal respiration (Fig. 4C and D) and spare respiratory capac-
ity (Fig. 4E). Insulin resistance-mediated decreased SIRT2
and modified mitochondrial function appear to be related to
unbalanced mitochondrial dynamics and decreased TFAM-
dependent mitochondrial biogenesis. Indeed, to maintain their
function mitochondria constantly undergo fusion and fission
events; simultaneously, novel mitochondrial components are
being formed and the organelle is degraded. The disruption of
these dynamics may underlie the pathogenesis of insulin resis-
tance in obesity and type 2 diabetes (38,39). Interestingly, we
found that SIRT2 could ameliorate the changes in TFAM levels
and thus mitochondrial mass. Considering that PGC-1a coacti-
vates nuclear respiratory factors (NRF-1 and NRF-2), which regu-
late the expression of TFAM, and that SIRT2-/- mice exhibited
increased PGC-1a acetylation (40), we may anticipate that re-
duced TFAM-dependent biogenesis in insulin resistant condi-
tions may be linked to increased acetylation and thus decreased
activity of PGC-1a. SIRT2 was also shown to reverse the
derangement of mitochondrial dynamics by re-establishing a
tubular mitochondrial network, which was mechanistically
linked to enhanced levels Mfn2 and decreased Drp1 in mito-
chondria. Notably, in contrast with Liu et al. (40), we did not de-
tect SIRT2 in mitochondrial fractions isolated from hepatocyte
cells, implicating that its deacetylase activity might be required
to modulate both mitochondrial dynamics and function, possi-
bly by modifying primarily cytosolic proteins, such as Drp1.
Another potential mechanism linking SIRT2 downregulation
and insulin resistance is the ERK1/2 pathway. It is widely
accepted that insulin can activate both phosphoinositide 3-ki-
nase (PI3K)/Akt pathway, which is responsible for glucose me-
tabolism, and several proteins in the MAPK signaling pathway
(c-Jun NH2-terminal kinase [JNK], p38 and ERK1/2), which
results in decreased insulin signaling and is crucial for insulin
resistance (49). In the current study, we demonstrate that low
SIRT2 levels in both insulin-resistant livers and HepG2 cells are
associated with exaggerated phosphorylation of ERK1/2 and in-
creased production of ROS, indicating that ERK1/2 activation
seems a causal factor for insulin resistance caused by oxidative
stress. Accordingly, oxidative stress induces insulin resistance
in cardiomyocytes and hearts of diabetic mice, which is associ-
ated with ERK overactivation (50). Moreover, ERK inhibition
reversed the impaired insulin sensitivity (50). Collectively, our
observations suggest that increased ROS levels, ERK1/2 activa-
tion and mitochondrial dysfunction together with SIRT2 defi-
ciency, may decrease insulin signaling in vitro and in vivo to
promote the development of insulin resistance.
SIRT2 mRNA and/or protein levels in PBMCs may represent a
potential and novel pathogenic marker of insulin resistance in
humans. PBMCs are readily accessible biological material and,
more importantly, their gene expression is representative of
whole metabolic status (51,52). Although the biological regulation
of SIRT2 in PBMCs may not parallel that in insulin-responsive tis-
sues, such as the liver, a recent study demonstrated that SIRT2
gene expression in PBMCs of obese subjects was induced by calo-
rie restriction (20). In addition, the surrogate measure of insulin
resistance used in this study (HOMA-IR) correlates reasonably
well with the insulin clamp (53), and primarily reflects hepatic in-
sulin sensitivity, since the fasting plasma glucose is determined
mainly by the rate of hepatic glucose production (HGP) and insu-
lin is the primary regulator of HGP. Although we cannot translate
this observation directly to other insulin-sensitive cells, we hy-
pothesize that this relationship may also be true in tissues that
play a relevant role in determining insulin resistance.
In conclusion, our work proposes SIRT2 as an important reg-
ulator of insulin sensitivity and may represent a novel thera-
peutic approach for the prevention and/or treatment of insulin
resistance and its associated comorbidities.
Materials and Methods
Mice
Experimental procedures complied with the Declaration of
Helsinki and have been approved by the Ethics Committee of
the University of Porto. Mice were purchased from Charles River
and housed in a temperature-controlled (20–22 C) room on a
12-h light/dark cycle, and chow and water were provided ad libi-
tum. Eight-week-old male ob/ob mice and their age-matched
lean control C57BL/6 J mice were anesthetized using sodium
pentobarbital (60 mg/kg, i.p.) and blood and liver tissue were col-
lected. Fasting blood glucose and plasma insulin concentrations
were used for the estimation of HOMA-IR (54). Eight-week-old
C57BL/6 J mice were fed either a CD or a HFD (D12492, Research
Diets) for 21 weeks. A blood sample was obtained by nicking the
lateral tail vein to measure glycemia with a glucometer after
overnight fasting.
Cell culture, treatment and transfections
HepG2 human hepatoma cells were obtained from American
Type Culture Collection. Cells were maintained in MEM (Sigma)
supplemented with 10% heat-inactivated FBS (Gibco) and 1%
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penicillin/streptomycin. Cells were maintained at 37 C under a
humidified atmosphere with 5% CO2. To induce insulin resis-
tance, HepG2 cells were treated with 20 mM glucosamine for
24 h in serum-free MEM. Under these conditions, there was no
significant effect on cell viability (data not shown). All transfec-
tions consisted in combining Lipofectamine 2000 reagent
(Invitrogen) with Opti-MEM followed by the addition of the plas-
mid of interest. The resulting complexes were then added to the
cells and incubated for 48 h.
Measurement of H2O2 production
Fresh liver tissue from WT and ob/ob mice was cut into square
pieces and incubated at 37 C in Krebs-HEPES buffer (118 mM
NaCl, 4.5 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, 1.2 mM K2HPO4,
25 mM NaHCO3, 25 mM Na-HEPES, and 5 mM glucose; pH 7.4) for
90 min, with oxygenation and constant shaking, as previously
described (29). After incubation, the resulting supernatants were
transferred to a 96-well plate and tissues were weighed to nor-
malize final results. HepG2 cells were cultured in 96-well plates,
treated and the medium transferred to a replica plate. H2O2 re-
leased from tissue or cells was then detected using the Amplex
Red Hydrogen Peroxide/Peroxidase assay kit (Molecular Probes),
following manufacturer‘s instructions. Fluorescence intensity
was measured in a Spectramax Gemini XS microplate reader
(Molecular Devices) at an excitation wavelength of 530 nm and
emission wavelength of 590 nm, for 40 min at room temperature,
following the kinetics of the reaction (every 1 min).
Western blot analysis
For total protein lysates, liver tissue or HepG2 cells were homog-
enized in ice-cold radioimmunoprecipitation assay (RIPA) buffer
(50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA)
containing protease and phosphatase inhibitors. For cytosolic
and mitochondrial-enriched fractions, HepG2 cells were homog-
enized with a Potter-Elvejhem 377 homogenizer with a Teflon
pestle, at 300 rpm, in ice-cold sucrose buffer (250 mM sucrose,
20 mM HEPES/KOH (pH 7.5), 100 mM KCl, 1.5 mM MgCl2, 1 mM
EGTA, 1 mM EDTA), supplemented with protease and phospha-
tase inhibitors. Resulting lysates were centrifuged at 1, 088 x g
for 12 min (4 C) to pellet the nuclei and cell debris. The superna-
tant was further centrifuged at 12, 000 x g for 20 min (4 C) and
the resulting pellet (mitochondrial-enriched fraction) re-
suspended in supplemented sucrose buffer. Trichloroacetic acid
(15%) was added to the supernatant, and precipitated proteins
were centrifuged at 16, 300  g for 10 min (4 C). The resulting
pellet (cytosolic fraction) was re-suspended in supplemented su-
crose buffer and brought to pH 7 with KOH. Protein concentra-
tions were quantified using the BCA protein assay kit (Pierce).
Equal amounts of total protein (30–50 mg) were separated by 10%
SDS-PAGE, transferred to nitrocellulose membranes, and incu-
bated for 1 h with a blocking solution (5% nonfat dry milk, 0.1%
Tween-20 in TBS). Immunodetection was performed using anti-
P-ERK1/2 (Cell Signaling), anti-ERK1/2 (Cell Signaling), anti-SIRT2
(Sigma Aldrich), anti-GFP (Santa Cruz), anti-TFAM (Abcam), anti-
Drp1 (BD Biosciences), anti-Mitofusin 2 (Sigma), anti-Opa1
(BD Biosciences), anti-GAPDH (Santa Cruz) and anti-actin (Santa
Cruz) antibodies. A 1: 20, 000 dilution of the appropriate fluores-
cently labeled secondary antibodies (Rockland) were used to de-
tect the resulting immune complexes. Detection was performed
using Odyssey infrared imaging system (LI-COR Biosciences).
Glycogen synthesis
HepG2 cells were seeded at a density of 6 104 cells/cm2 in
24-well culture plates. After 24 h, cells were washed with
serum-free MEM and incubated for 24 h with the same medium
in the presence or absence of 20 mM glucosamine. The medium
was then replaced by 500 ml of MEM containing 1 mCi/ml
D-[3 H]glucose and incubated in the presence or absence of
100 nM insulin for 3 h. Cells in each well were then lysed in
200 ll of 30% KOH with 5 mg/ml glycogen for 30 min at 60 C. Cell
lysates were transferred to polypropylene tubes, and glycogen
was precipitated overnight at 20 C by adding 1 ml of absolute
ethanol. Glycogen was then separated by centrifugation at
5000 g for 10 min, and the pellets washed twice with 75% ice-
cold ethanol. Finally, the pellets were solubilized in 200 ml of
0.1 M HCl and measured in a liquid scintillation counter by add-
ing 4 ml of high-flashpoint scintillation cocktail.
Oxygen consumption in intact HepG2 cells
Oxygen consumption was measured with a Clark-type oxygen
electrode. Each experimental condition was analyzed by incubat-
ing 1.5 106 cells in PBS in a magnetically stirred chamber thermo-
stated to 37 C. After recording basal respiration, uncoupled
respiration (proton leak) was measured by adding 2.5mg/ml of ATP
synthase inhibitor oligomycin (Sigma). Subsequently, 1mM of
cyanide p-trifluoromethoxyphenylhydrazone (FCCP, Sigma) was
added to the chamber to measure maximum respiration.
Mitochondrial spare respiratory capacity (SRC) was calculated by
subtracting the basal respiration to the maximal respiration
(SRC¼ FCCP-driven respiration – basal respiration).
Immunocytochemistry
HepG2 cells plated in gelatin-coated 16 mm coverslips were
washed twice with warm PBS, fixed with 4% paraformaldehyde
for 20 min, permeabilized in 0.1% Triton X-100 in PBS for 2 min
and blocked for 1 h, at room temperature in 3% (w/v) BSA in PBS.
Incubation with anti-Drp1 primary antibody (1: 300, BD biosci-
ences) occurred overnight, at 4 C. In the following day, cells
were incubated for 1 h, at room temperature, with secondary
antibody alexa fluor-633 donkey anti-mouse (1: 300, Molecular
Probes). All antibodies were prepared in 3% (w/v) BSA in PBS.
Finally, cells were incubated with Hoechst 33342 (4lg/ml) for
20 min and mounted using fluoroshield mounting medium
(Abcam).
Image acquisition and analysis
Confocal images were obtained using a Plan-Apochromat/
1.4 NA 63x lens on an Axio Observer.Z1 confocal microscope
(Zeiss Microscopy, Germany) with Zeiss LSM 710 software.
Mitochondria area, morphology and protein co-localization
analysis was achieved using Macros for Fiji designed by Dr.
Jorge Valero (Achucarro Basque Center for Neuroscience, Spain),
in Fiji. Briefly, nonspecific background noise was corrected using
the Subtract Background function included in Fiji (rolling ball
radius: 10 lm for 8 bit transformed images). For analysis of
mitochondrial network HepG2 cells were transfected with cyto-
chrome c oxidase subunit VIII-targeted DsRed (MitoDsRed,
Clontech). FindFoci function was used to allow the identification
of peak intensity regions and a threshold was applied to
optimally create a mitochondrial mask with individualized
mitochondria. Mitochondrial network was traced through
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Analyze Particles function and Aspect ratio (ratio between the
major and minor axis of mitochondria) was used as an index of
mitochondrial length. For protein co-localization with mito-
chondria a threshold was set and the Integrated Density
(Int. Den.) measured inside the mitochondrial region of interest.
Data were normalized for cellular area.
Human studies
The study protocols were conducted in accordance with the
aforementioned institutional guidelines. Subjects (n¼ 45) were
selected from the Epidemiological Health Investigation of
Teenagers in Porto (EPITeen) cohort and followed at the
Department of Clinical Epidemiology, Predictive Medicine and
Public Health of the University of Porto. The recruitment and
characteristics of the cohort were previously described (55). The
nature and potential risks of the study were explained to all
subjects before obtaining their written informed consent. Each
subject completed a questionnaire to collect history regarding
smoking and alcohol consumption, as well as other demo-
graphic characteristics, such as age and family history of can-
cer, diabetes, and cardiovascular disease. Exclusion criteria
included regular exercise (>90 min of aerobic activity per week),
usage of medications (e.g. antidiabetics) or dietary supplements
(e.g. antioxidants), and a known history of disease (i.e. type 2 di-
abetes, dyslipidemia, or arterial hypertension). Participants
were instructed to abstain from smoking and alcohol consump-
tion at least 24 h before the study. Anthropometric measure-
ments including height, weight and waist circumference, were
taken according to standardized procedures. Body fat percent-
age was measured with a bioimpedance analyzer of body com-
position. For the present analysis, we included subjects with a
body mass index (BMI) ranging from 15 to 40 kg/m2. BMI was
calculated as weight (in kilograms) divided by square of height
(in meters). Subjects were stratified into two BMI groups: normal
(BMI< 25 kg/m2) and overweight/obese (BMI> 25 kg/m2).
PBMCs isolation and measurement of biomarkers
After informed consent, participants provided a peripheral
blood sample. Plasma and peripheral blood mononuclear cells
(PBMCs) were isolated from whole blood by density gradient
centrifugation on Histopaque 1077 (Sigma). Plasma samples
were analyzed for fasting glucose, insulin, triglycerides, total
cholesterol and high-density lipoprotein (HDL) and low-density
lipoprotein (LDL). Insulin resistance was evaluated by the
HOMA-IR (54). Plasma samples were also analyzed for thiobarbi-
turic acid reactive substances (TBARS), as a marker of lipid
peroxidation, using a spectrophotometric method (56).
Total RNA extraction and quantitative real time PCR
Total RNA was extracted from livers of CD- and HFD-fed mice
and from PBMCs isolated from human blood samples using
Trizol (Invitrogen), according to manufacturer‘s instructions.
cDNAs were produced using first strand cDNA synthesis kit
(Fermentas). Quantitative PCR was performed in a StepOne Plus
Real Time PCR system (Applied Biosystems) using SIRT2 and
actin primers. All PCR reactions were performed in triplicate
and amplified using Kapa SYBR Fast Universal qPCR kit
(Kapa Biosystems). Relative quantification of SIRT2 gene expres-
sion normalized to actin or b-2-microglobulin housekeeping
genes was carried out using the comparative CT method.
Microarray analysis was performed on published transcriptom-
ics (GEO GSE32095). Heat maps were generated using GENE-E
(http://www.broadinstitute.org/cancer/software/GENE-E/index.
html), and rows were clustered using the one minus Pearson
correlation metric.
Data analysis
Statistical analyses were performed with SPSS Version 19.0. All
data are presented as mean6SEM, except for data in Table 2,
which are presented as mean6SD. Normal distribution was
verified with the Kolmogorov-Smirnov test. Differences be-
tween two groups were assessed using the Student‘s unpaired t
test or the Mann-Whitney test, for normally and not normally
distributed variables, respectively. Comparisons between multi-
ple groups were performed using one-way analysis of variance
(ANOVA). Associations among variables were assessed with the
use of Pearson‘s correlation coefficient. Differences were con-
sidered statistically significant at P< 0.05.
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